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Background: The prevalence of allergic diseases has increased in recent decades but the causes 43 
remain unclear. Changes in the epidemiology of childhood infections could have contributed but the 44 
current evidence is inconclusive. This study aims to investigate whether age at cytomegalovirus 45 
(CMV), Epstein Barr virus (EBV) or varicella zoster virus (VZV) infection are associated with the 46 
development of atopy. 47 
Methods: 2559 children were enrolled in the Born in Bradford Allergy and Infection Study. Serum 48 
samples collected at 12 and 24 months were tested for CMV-IgG, EBV-IgG and VZV-IgG for 1000 49 
children to establish age at infection. Skin prick testing (SPT) was conducted at age 4 years.  50 
Results: Serology and SPT results were available for 740 children. Of these, 135 (18%) were atopic. In 51 
girls there was a strong association of CMV infection in the second year with increased odds of atopy 52 
(adjusted OR 4.38, 95% CI 1.87–10.29) but this was not observed in boys. Age at EBV or VZV 53 
infection were not associated with risk of atopy in unadjusted analysis, but there was effect 54 
modification by sex; girls infected with VZV in the second year of life had increased odds of atopy 55 
(adjusted OR 2.85, 95% CI 1.29 – 6.30). 56 
Conclusions: Our results highlight potential sex-specific effects of age at CMV infection and age at 57 
VZV infection on risk of atopy, which provide insight into the mechanisms involved in the 58 
development of atopy. 59 
233 words 60 
 61 
 62 





The hygiene hypothesis proposes that the dramatic rise in prevalence of eczema, hay fever and 66 
allergic asthma in recent decades is due to a reduction in childhood infections1,2. However, many 67 
studies have investigated proxy measures for childhood infections such as birth order and child 68 
care3,4 or have focussed on symptomatic, clinically diagnosed infections5-7. 69 
Cytomegalovirus (CMV), Epstein Barr virus (EBV) and varicella zoster virus (VZV) are persistent 70 
herpesviruses commonly acquired in childhood. CMV and EBV are usually asymptomatic and VZV 71 
causes chickenpox. There is good evidence that CMV and EBV affect the developing immune 72 
system8,9. CMV impacts on T cell10 and NK cell11,12 differentiation and CMV seropositivity is 73 
associated with inflammation, atherosclerosis and immunosenescence13,14. EBV is associated with 74 
immune disorders such as multiple sclerosis and lymphoma15,16. The features of CMV and EBV in 75 
particular indicate that changes in the epidemiology of these infections could have contributed to 76 
the increases in eczema, hay fever and allergic asthma. 77 
In a Swedish study no association was found between CMV or EBV seropositivity at age 4 and 78 
asthma, hay fever or eczema, although CMV positive/EBV negative children were more likely to have 79 
specific IgE to common allergens than children seronegative for both infections17,18. In another study, 80 
children who were EBV seropositive at 24 months were less likely to be IgE-sensitised at this age 81 
compared to EBV seronegative children and this association was enhanced among children co-82 
infected with CMV19. Another analysis by the same group showed that children infected with EBV 83 
before 2 years were less likely to be IgE-sensitised at age 2 and 5 years while those infected after 2 84 
years were more likely to be IgE-sensitised at 5 years20. 85 
There was no association between CMV, EBV or VZV infection at age 12 months and eczema, 86 
asthma, hay fever, total serum IgE levels or allergic sensitisation at age 7 in a German study21. In a 87 
UK case-control study there was no association between EBV or VZV infection and eczema in 1-4 88 
year olds22. Other studies have examined the association between seropositivity to CMV, EBV, VZV 89 
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and other infections and risk of atopy or eczema, hay fever, or asthma, but the combined evidence is 90 
inconclusive23-25. In some, the findings were limited by a lack of statistical power but in most, 91 
infection status was measured at only one time point, often at age 4 or older, so it was not possible 92 
to pinpoint age at infection more precisely. As herpesvirus infections are common it is unlikely that 93 
infection per se is associated with risk of disease, but alteration in risk could result from infection at 94 
a critical period in immune development. Measuring infection status at more than one age in the 95 
first years of life is therefore important. In the Born in Bradford Allergy and Infection Study, children 96 
were tested for CMV-, EBV- and VZV-IgG at 12 and 24 months. We have previously reported earlier 97 
infection in Pakistani compared to white British children26. The aim of this analysis is to investigate 98 
whether earlier CMV and/or EBV infection protect against the development of atopy. 99 
 100 




The Allergy and Infection Study (ALL IN) is a sub-study of the Born in Bradford birth cohort (BiB), 103 
described elsewhere27. Children were eligible to participate if they were enrolled in BiB with a 104 
maternal baseline questionnaire available and were born on or after 1 March 2008. Parents were 105 
invited to participate in ALL IN just before the child’s first birthday. If they agreed, a home or clinic 106 
visit was arranged and informed consent obtained. A blood sample was taken and a questionnaire 107 
completed at 12 months and again at 24 months of age. Serum aliquots were stored at -800C. The 108 
questionnaires included detailed information on breastfeeding and child care, and the standard 109 
International Study of Asthma and Allergies in Childhood (ISAAC) questions on potential risk factors 110 
for atopy (pets, damp, mould, fuel for cooking and heating, type of windows in the child’s bedroom, 111 
type of flooring, type of pillow and bedding for the child)28.  112 
Of the 2559 children enrolled in ALL IN, serum samples were tested for CMV-IgG, EBV-IgG and VZV-113 
IgG for 1000 children to establish age at infection; infected by 12 months, infected between 12 and 114 
24 months; or uninfected at 24 months26. Samples with concentration values of ≥6.0 AU/mL were 115 
considered as positive for CMV-IgG, and VCA IgG concentrations of ≥20 U/mL were considered as 116 
positive for EBV-IgG. For VZV, samples containing 160 mIU/ml were considered positive, those 117 
between 140 and 160 were equivocal and those less than 140 mIU/ml were deemed negative. 118 
When the children were 4 years old the parents were re-contacted and invited for a visit including a 119 
questionnaire and skin prick test (SPT), as part of the MeDALL (Mechanisms of the Development of 120 
Allergy) study29,30. The SPT was performed according to a standard protocol using the following 121 
allergens: cat hair, dog hair, grass mix, house dust mites Dermatophagoides pteronyssinus and 122 
Dermatophagoides farinae plus a positive control (histamine 1%) and a negative saline control 123 
(Allergopharma kits supplied by Diagenics Ltd). The mean wheal diameter was recorded for each 124 
allergen (and the diameter of any wheal from the negative control subtracted). A wheal diameter of 125 
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>=3mm was considered a positive reaction. Children with a positive reaction to at least one allergen 126 
were defined as atopic. 127 
The community research staff were trained in SPT, with quality control procedures to assess intra-128 
observer variability; all staff had to perform two-monthly quality checks and achieve a coefficient of 129 
variation of less than 20 in their SPT series. 130 
Parents were given the results of their child’s SPT with written guidance on allergen avoidance for 131 
those with positive tests. 132 
This study had ethical approval from the London School of Hygiene & Tropical Medicine ethics 133 
committee (refs: 5320 and 6249) and the Bradford Research Ethics committee (refs: 08/H1302/21 134 
and 12/YH/0252).   135 
Statistical analysis 136 
Data analysis was conducted using Stata version 1431. Frequency distributions for key variables 137 
described the children and their mothers. Cross-tabulations showed associations between these 138 
variables and atopic status. Age at CMV, EBV and VZV infection were the key exposures of interest. 139 
The outcome for this analysis was measured at age 4 years only and in all children at the same age. 140 
Our data therefore provide an estimate of prevalence, not risk, of atopy so it is appropriate to 141 
present prevalence odds ratios from logistic regression analysis. If univariable analysis demonstrated 142 
an association with atopy, the relevant variable was included as a confounder in the multiple logistic 143 
regression analysis. The findings for age-at-CMV infection were compared between the univariable 144 
and multiple logistic regression analyses, and no evidence of multicollinearity was found, so the 145 
multiple regression analysis was accepted as the final model. Birth order and duration of 146 
breastfeeding were included in the CMV model a priori as these are strongly associated with age at 147 
CMV infection26 and associated with atopy in other studies32-34. Effect modification by sex and ethnic 148 
group were investigated35. 149 
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Previous studies have indicated interaction between EBV and CMV infection on atopy/IgE 150 
sensitisation18,19 so we compared the proportion of children who were atopic for combinations of 151 
age at CMV/EBV/VZV infection. 152 
The number and type of positive allergens per child were described and examined by ethnic group 153 




SPT was completed at the 4-year visit for 740 children with serological data. Of these, 135 (18%) 156 
were atopic (95% CI 16–21). 157 
Table 1 shows the characteristics of the children and their mothers.  158 
Unadjusted analysis 159 
Among the children who were CMV infected by 12 months and those who remained uninfected at 160 
24 months, 17% were atopic (31/181 and 82/485, respectively). However, of the 74 children who 161 
were CMV infected between 12 and 24 months, 30% (22) were atopic. There were no differences in 162 
the proportion of children atopic by age at EBV infection or by age at VZV infection (18 or 19% in 163 
each group). 164 
Boys were twice as likely to be atopic than girls and Pakistani children were twice as likely to be 165 
atopic than White British children. Childcare attendance by age 24 months, reporting pets in the 166 
home and central heating at the 12-month visit, and smoking in pregnancy were associated with 167 
reduced risk of atopy.  Low birth weight and damp reported at 12 months were associated with an 168 
increased risk of atopy. There was not strong evidence of an association with pets and damp 169 
reported at the 24-month visit (Table 1). There was no evidence of associations between atopy and 170 
mould in the home, type of windows in child’s bedroom, gas for cooking, gas fire, wood or coal fire 171 
with chimney, type of flooring or bedding (data not shown). 172 
Only nine respondents reported making changes due to asthma/allergies (mainly changing to hard 173 
floors or new carpets, different bedding) at the 12-month questionnaire (3 were atopic) and only 17 174 
reported making changes at the 24-month questionnaire (5 were atopic).  175 
The associations of atopy with breastfeeding, childcare, pets and smoking in pregnancy may reflect 176 
differences in the prevalence of these factors between white British and Pakistani children; Pakistani 177 
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women were more likely to breastfeed, less likely to use childcare and far less likely to smoke than 178 
white British women. Pakistani families were less likely to have pets than white British families. 179 
The 740 children included here were generally similar to the total 1000 children with serological 180 
data, although there was a slightly higher proportion of Pakistani children. 181 
Adjusted analysis 182 
There was some evidence of effect modification of the association between age at CMV infection 183 
and atopy by sex (LRT =4.80, p=0.09), adjusting for ethnic group, birth order, duration of 184 
breastfeeding, regular childcare attendance by 24 months, low birth weight, pets in the home (12 185 
months), damp (12 months), smoking pregnancy and central heating (12 months). In boys there was 186 
no association between CMV infection in the second year and odds of atopy (adjusted OR (aOR) 187 
1.20, 95% CI 0.52–2.79) and weak evidence of a protective effect of infection before 12 months (aOR 188 
0.57, 95% CI 0.31–1.04). In girls there was a strong association of CMV infection in the second year 189 
with increased odds of atopy (aOR 4.38, 95% CI 1.87–10.29) and no association with infection in the 190 
first year (aOR 0.97, 95% CI 0.40–2.33) (Table 2).  191 
There was also evidence of effect modification by sex of the association between age at EBV 192 
infection and atopy (LRT =5.87, p=0.05) and age at VZV infection and atopy (LRT =8.52, p=0.01); 193 
the sex-specific estimates are presented in Table 2. Girls infected with VZV in the second year of life 194 
were at increased odds of atopy (aOR 2.85, 95% CI 1.29 – 6.30). There was no evidence of effect 195 
modification by ethnic group of the association between age at CMV, EBV or VZV infection and 196 
atopy. 197 
Table 1 shows the adjusted estimates (from the model for age at CMV infection) for the other 198 
variables associated with atopy. Boys had three times the odds of atopy overall compared to girls. 199 
The increased risk of atopy among Pakistani compared to White British children attenuated in 200 
multivariable analysis.  There was weak evidence that children of low birth weight, those breastfed 201 
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for more than 12 months and children living in homes without central heating had around twice the 202 
odds of atopy. There was good evidence that children living in damp homes were more likely to be 203 
atopic. 204 
 205 
Infection with more than one virus in the second year is associated with greater risk of atopy 206 
Of the total 740 children, 23 were infected with CMV and EBV between 12 and 24 months; 8 of 23 207 
(35%) were atopic. Among 33 children who were CMV and EBV infected by 12 months, 6 (18%) were 208 
atopic. Similarly, among 121 children who were CMV and EBV infected by 24 months, 25 (21%) were 209 
atopic. Of 20 children who were CMV and VZV infected between 12 and 24 months, 9 (45%) were 210 
atopic and of 5 children who were infected with all three viruses between 12 and 24 months, 4 211 
(80%) were atopic. The final model for age at CMV infection, stratified by EBV infection status at 24 212 
months gave similar estimates to the overall results (data not shown). 213 
Ethnic group differences in atopy 214 
Among 386 Pakistani mothers, 250 were born outside, and 136 were born in, the UK. 64 (26%) 215 
children of those born outside the UK were atopic compared to 25 (18%) children of women born in 216 
the UK (χ2=2.59, p=0.11).  27 (11%) children of White British women born in the UK were atopic. 217 
Only two of the White British women were born abroad (and one child was atopic). 218 
Which allergens were positive? 219 
There were five allergens in the panel. Most of the 135 atopic children were positive for one (n=56) 220 
or two (n=52) allergens (Table 3).  Positive reactions to house dust mites (HDM) were most common, 221 
followed by grass mix with positive cat and dog results the least common. The number of positive 222 
allergens per child did not vary substantially by ethnic group or sex. 223 
Pakistani children were more likely to have a positive test for HDM than White British children. 224 
Among 56 children who reacted to one allergen, 33 (83%) of 40 Pakistani children were positive to 225 
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HDM compared to 5 (50%) of the 10 White British children (χ2=4.63, Fisher’s exact p=0.05). All 226 
except two children (1 WB, 1 Pakistani) with two positive reactions and all except one child (WB) 227 
with three positive reactions were positive for at least one HDM. 228 
Among 56 children who reacted to one allergen, a higher proportion of boys were positive to HDM 229 
than girls but there was no evidence of a true difference (χ2=1.38, p=0.24). Among 52 children who 230 
reacted to two allergens, all except one boy and one girl were positive for one or both HDM, and 231 
among 21 children with three positive reactions, all except one boy were positive for one or both 232 
HDM.  233 




Our main finding is that, among the girls, CMV infection in the second year of life is associated with a 236 
4–fold increased odds of atopy compared to acquiring it in the first year or remaining uninfected at 2 237 
years. Among the boys there was no association between infection at 12-24 months and atopy, but 238 
weak evidence of a protective effect of CMV infection in the first year of life on odds of atopy. 239 
Although age at EBV infection and age at VZV infection were not associated with risk of atopy in 240 
unadjusted analyses, there was good evidence of effect modification by sex. Stratified, adjusted 241 
estimates revealed an increased odds of atopy among girls infected with VZV in the second year of 242 
life compared to those still uninfected at 2 years. 243 
Traditionally, until 50-70 years ago in the UK and in low income countries today, most children 244 
became infected with CMV by the age of 12 months36,37. One explanation for our findings is that 245 
‘delayed’ infection,  coinciding with immune development in the second year of life, may disrupt the 246 
balance of immune responses, leading to atopy. A second potential explanation is that CMV 247 
infection acquired when maternal antibody titres are declining might present a lower initial viral load 248 
to the immune system than found with perinatal infection from breast milk or infection later in life. 249 
Further studies are needed on this and should be linked to our observation of increased atopy in 250 
those of low birth weight who would have reduced transplacental passage of IgG.  251 
The consistent direction of the sex-specific estimates for CMV, EBV and VZV, with increased odds of 252 
atopy among girls infected in the second year with CMV and with VZV, supports the biological 253 
plausibility of a sex-specific mechanism in the development of atopy. The ‘critical window’ seems to 254 
be the second year of life when also considering combinations of CMV, EBV and VZV infection; the 255 
highest proportion of atopic children were among those infected in the second year of life with one 256 
or more of the viruses. Some evidence of a protective effect of CMV infection in the first year of life, 257 
at least in boys, fits with the traditional age at infection and corresponding low prevalence of atopy, 258 
and demonstrates the importance of differentiating between infection in the first and second years.  259 
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Our results highlight potential sex-specific effects of age at CMV infection on risk of atopy. Overall, 260 
boys had a greater risk of atopy than girls, as reported in other studies38,39, but differences in risk of 261 
atopy by age at CMV infection were only observed for girls. So why is ‘delayed’ CMV infection 262 
associated with atopy in girls but not in boys?  263 
There are other examples of sex differences in response or susceptibility to infections early in life40,41 264 
and neonatal vitamin A supplementation (NVAS) was associated with increased atopy in girls but not 265 
boys in long-term follow-up of children enrolled in a previous randomised controlled trial in Guinea-266 
Bissau42. As in our study, females were less likely to be atopic than males overall, but those receiving 267 
NVAS were at increased risk of atopy (adjusted RR=1.78, 95% CI 1.17–2.71) and wheeze during 268 
childhood (adjusted RR=1.78, 95% CI 1.02–3.09) compared to those receiving placebo. Possible 269 
mechanisms to explain these associations are that retinoic acids from vitamin A can lead to an 270 
enhanced Th2 response and a reduced Th1 response. High oestrogen levels can also promote a Th2 271 
response and girls experience surges in oestrogen levels in early infancy as well as in puberty. A 272 
further study by the group demonstrates that NVAS is associated with differences in response to 273 
BCG vaccination by sex and increased pro- to anti-inflammatory cytokine ratios in females but 274 
decreased ratios in males, at 4- 6 months of age43.  275 
In the Generation R cohort (population-based cohort from fetal life onwards, in Rotterdam, the 276 
Netherlands) no interaction of sex and CMV infection was observed in relation to immune 277 
phenotypes but the children were tested at age 6 years35, so differences by age at infection could 278 
not be investigated. In exploratory studies of the same cohort, an impact of female sex and CMV 279 
infection on immune cell dynamics in early childhood has been demonstrated44. 280 
The combined evidence indicates that the sex-specific associations we have observed may provide 281 
clues about the mechanisms involved in the development of atopy. There is evidence that CMV 282 
influences anti-inflammatory mediators (viral and host IL-10)45. CMV infection may therefore 283 
influence the Th1/Th2 balance particularly in the second year of life, and this, combined with 284 
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hormonal effects in girls, could increase the risk of atopy. It is also possible that the reverse is true: 285 
early immune changes which lead to atopy may be associated with delayed CMV infection.  286 
The group of children who were CMV infected in the second year is relatively small, only 10% of the 287 
total, and the majority of children in this cohort remained uninfected at age 2 years. Their risk of 288 
atopy was similar to those infected in the first year and we do not know the age distribution of 289 
subsequent CMV infection in this group. However, we assume that CMV infection during early 290 
immune development, i.e. the first 2-3 years, influences risk of atopy at age 4 years, and later 291 
infection has less impact. 292 
We did not observe any differences in risk of atopy by age at EBV infection, in contrast to the 293 
Swedish studies19, although there was evidence of effect modification by sex. EBV infection tends to 294 
be acquired later than CMV; in this cohort most of the CMV infections occurred in the first year, 295 
usually through contact with the mother whereas most EBV infections occurred in the second year 296 
via contact with siblings and other children26. Delayed infection for EBV is therefore around age 3 or 297 
4 years and older. A comparison of children infected by age 2 years (the ‘traditional’ age at infection) 298 
with those infected between 2 and 4 years (delayed infection) would demonstrate any effect on risk 299 
of atopy and we did not carry out serological testing at age 4 years. However, an effect on atopy risk 300 
would only be expected if the delayed infection coincided with a critical period of immune 301 
development. Similarly, VZV infection is usually acquired around age 3 or 4 years through contact 302 
with other children and we show that infection during the second year of life, a likely critical period 303 
of immune development, is associated with increased odds of atopy. 304 
The 18% prevalence of atopy in our study is generally consistent with results from other European 305 
birth cohorts19,46 and UK studies47,48.  Some of these measured allergen specific IgE (sIgE) in serum 306 
rather than SPT and the children included ranged from age 2 to 7 years with all primary school-aged 307 
children included in one study. 308 
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The higher odds of atopy among Pakistani children, although attenuated in multivariable analysis, 309 
especially when including childcare in the model, is of interest and there was some evidence of a 310 
higher risk of atopy in children of women born abroad and recently migrated to the UK. In the US 311 
NHANES study allergic sensitisation was associated with ethnicity and among those aged 1 to 5 years 312 
was less prevalent in non-Hispanic white children than other ethnic groups39.  The number of 313 
positive allergens per child did not vary by ethnicity but there was weak evidence that Pakistani 314 
children were more likely to have a positive test to HDM than White British children. Higher levels of 315 
HDM and sensitisation to HDM have been associated with damp in the home49. In our study a higher 316 
proportion of Pakistani children had damp in the home at 12 months than White British children, 317 
which might partly explain the higher odds of atopy in Pakistani children. 318 
The key strength of our study is having infection status at both 12 and 24 months. To our knowledge, 319 
this is the first study to measure CMV- and EBV-IgG at 12 and 24 months in relation to atopic status. 320 
The benefits of the cohort design included risk factor data collected at 12 and 24 months, and at 4 321 
years, whereas cross-sectional studies may not capture earlier exposures accurately either due to 322 
recall bias or if there are changes between age one and four years, which may have been made in 323 
response to allergic symptoms. There were few reported changes due to asthma or allergies at the 324 
12 and 24-month questionnaire. 325 
SPT is widely used and accepted as a valid tool to define atopy28. Several members of the team 326 
carried out the tests and there may have been variations in technique between them, despite 327 
training and quality control checks. However, any measurement error and subsequent 328 
misclassification of atopic status would have been non-differential, as the research team were 329 
unaware of the infection status of the children. Some studies use sIgE to define atopic status, instead 330 
of, or in addition to, SPT. There is generally good correlation between sIgE and SPT (>70% 331 
concordance), at least in high income country settings50,51.  332 
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Not all children with a positive SPT will develop clinical symptoms of eczema, hay fever or allergic 333 
asthma. Some non-atopic children may develop different types of asthma caused by non-atopic 334 
mechanisms. Further work will investigate whether the higher odds of atopy among girls infected 335 
with CMV in the second year translates to an increased risk of eczema, hay fever, wheeze or asthma 336 
among these children. 337 
In conclusion, our results highlight potential sex-specific effects of age at CMV infection and age at 338 
VZV infection on risk of atopy, which may provide insight into the mechanisms involved in the 339 
development of atopy. 340 
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Table 1. Characteristics of the 740 children and their mothers and associations with atopy at age 4 years.  484 
Adjusted ORs only presented for variables included in the multiple logistic regression model for age at CMV infection.  485 
 
 
N (%) Number of 
children atopic 
(%) 
Unadjusted OR, 95% CI, p Adjusted OR, 95% CI, p 
Age at CMV infection     
By 12 months 181 (24%) 31 (17) 1.02 (0.65 – 1.60), 0.95 See table 2 for sex-specific 
estimates 12-24 months   74 (10%) 22 (30) 2.08 (1.20 – 3.61), 0.009 
Uninfected at 24 months 485 (66%) 82 (17) 1.0 
Age at EBV infection     
By 12 months 112 (15%) 21 (19) 1.07 (0.63 – 1.83), 0.80 See table 2 for sex-specific 
estimates 12-24 months 193 (26%) 37 (19) 1.10 (0.71 – 1.70), 0.66 
Uninfected at 24 months 435 (59%) 77 (18) 1.0 
Age at VZV infection     
By 12 months   66 (9%) 12 (18) 1.00 (0.52 – 1.95), 0.99 See table 2 for sex-specific 
estimates 12-24 months 128 (17%) 24 (19) 1.04 (0.64 – 1.71), 0.87 
Uninfected at 24 months 546 (74%) 99 (18) 1.0 
Mother’s ethnic group     
White British 258 (35%)   28 (11%) 1.0 1.0 
Pakistani 386 (52%)   89 (23%) 2.46 (1.56 – 3.89), <0.001 1.78 (0.96 – 3.31), 0.07 
Other   96 (13%)   18 (19%) 1.90 (0.99 – 3.61), 0.05 1.36 (0.65 – 2.85), 0.41 
Sex     
Female 343 (46%)   40 (12%) 1.0 1.0 
Male 397 (54%)   95 (24%) 2.38 (1.59 – 3.56), <0.001 3.28 (1.87 – 5.76), <0.001* 
Birth order     
1 257 (35%)   47 (18%) 1.0 1.0 
2 208 (28%)   31 (15%) 0.78 (0.48 – 1.28), 0.33 0.73 (0.43 – 1.25), 0.25 
3+ 275 (37%)   57 (21%) 1.17 (0.76 – 1.80), 0.48 0.86 (0.53 – 1.41), 0.56 
Duration of breastfeeding     
Never 126 (17%)   20 (16%) 1.0 1.0 
0-12 months 510 (69%)   88 (17%) 1.11 (0.65 – 1.88), 0.71 1.19 (0.66 – 2.13), 0.56 
>12 months 102 (14%)   26 (25%) 1.81 (0.94 – 3.48), 0.07 1.93 (0.93 – 4.00), 0.08 
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missing     2        
Regular childcare attendance by 24 months     
Ever 293 (40%)   41 (14%) 0.61 (0.41 – 0.91), 0.02 0.79 (0.49 – 1.29), 0.35 
Never 447    94 (21%)       1.0 1.0 
Low birth weight (<2500g)     
Yes   63 (9%)   16 (25%) 1.60 (0.88 – 2.91), 0.13 1.90 (1.00 – 3.62), 0.05 
No 677  119 (18%) 1.0 1.0 
Pets in the home (at 12 months)      
Yes 185 (25%)   25 (14%) 0.63 (0.39 – 1.01), 0.06 0.87 (0.50 – 1.49), 0.60 
No 550 109 (20%) 1.0 1.0 
missing    5    
Damp (damp spots on walls or ceilings) at 12 months     
Yes 168 (23%) 42 (25%) 1.70 (1.12 – 2.57), 0.01 1.68 (1.08 – 2.62), 0.02 
No 567 93 (16%) 1.0 1.0 
missing     5    
Smoking in pregnancy (asked at maternal baseline 
questionnaire) 
    
Yes   85 (12%)      9 (11%) 0.50 (0.24 – 1.02), 0.06 0.72 (0.33 – 1.57), 0.41 
No 654 126 (19%) 1.0 1.0 
missing     1    
Central heating at 12 months     
Yes 706 (96%)  126 (18%) 1.0 1.0 
No   30      9 (30%) 1.97 (0.88 – 4.41), 0.10 2.20 (0.93 – 5.19), 0.07 
missing     4    
Maternal education     
5 GCSE equivalent or less 334 (45%)   67 (20%) 1.0  
A level equiv & higher 341 (46%)   60 (18%) 0.85 (0.58 – 1.25), 0.41  
other/DK/foreign unknown   64 (9%)     8 (13%) 0.57 (0.26 – 1.25), 0.16  
missing     1    
Home ownership     
Yes 470 (64%)   85 (18%) 1.0  
No 269    50 (19%) 1.03 (0.70 – 1.52), 0.87  
missing      1    
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Maternal history of eczema, asthma or hay fever**     
Yes 284 (38%)   47 (17%) 0.83 (0.56 – 1.22), 0.35  
No 456   88 (19%) 1.0  
Paternal history of eczema, asthma or hay fever**     
Yes 231 (31%)   45 (19%) 1.13 (0.76 – 1.68), 0.56  
No 509   90 (18%) 1.0  
Term delivery (≥37 weeks)     
Yes 696 (94%) 127 (18%) 1.00 (0.46 – 2.21), 0.99  
No   44     8 (18%) 1.0  
Mode of delivery     
Vaginal 589 (80%) 106 (18%) 1.0  
Caesarean section 146   28 (19%) 1.08 (0.68 – 1.72), 0.74  
missing     5    
 486 
* Adjusted OR shows main effect of sex (i.e. among CMV uninfected) from the model including interaction term between sex and age at CMV infection 487 
** Similar results if limited to maternal/paternal history of eczema or hay fever (as not all asthma is atopic) 488 
  489 
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* adjusted for ethnic group, birth order, duration of breastfeeding, regular childcare attendance by 24 months, low birth weight, pets in the home (12 months), damp (12 504 
months), smoking pregnancy and central heating (12 months). 505 
  506 
   n No. atopic 
(%) 
Unadjusted OR, 95% CI, p Adjusted OR*, 95% CI, p 
n=732 
Girls Age at CMV 
infection 
By 12 months   77   9 (12) 1.43 (0.62 – 3.31), 0.41 0.97 (0.40 – 2.33), 0.94 
12-24 months   42 12 (29) 4.32 (1.90 – 9.78), <0.001 4.38 (1.87 – 10.29), 0.001 
Uninfected at 24 months 224 19 (8) 1.0 1.0 
Boys Age at CMV 
infection 
By 12 months 104 22 (21) 0.84 (0.49 – 1.46), 0.54 0.57 (0.31 – 1.04), 0.07 
12-24 months   32 10 (31) 1.43 (0.64 – 3.18), 0.38 1.20 (0.52 – 2.79), 0.67 
Uninfected at 24 months 261 63 (24) 1.0 1.0 
Girls Age at EBV 
infection 
By 12 months   47   3 (6) 0.60 (0.17 – 2.09), 0.42 0.42 (0.12 – 1.53), 0.19 
12-24 months   91 16 (18) 1.87 (0.92 – 3.78), 0.08 1.64 (0.79 – 3.39), 0.18 
Uninfected at 24 months 205 21 (10) 1.0 1.0 
Boys Age at EBV 
infection 
By 12 months   65 18 (28) 1.19 (0.64 – 2.21), 0.58 0.99 (0.52 – 1.90), 0.98 
12-24 months 102 21 (21) 0.81 (0.46 – 1.42), 0.45 0.72 (0.40 – 1.32), 0.29 
Uninfected at 24 months 230 56 (24) 1.0 1.0 
Girls Age at VZV 
infection 
By 12 months   32   2 (6) 0.57 (0.13 – 2.51), 0.45 0.52 (0.11 – 2.42), 0.41 
12-24 months   64 12 (19) 1.96 (0.93 – 4.14), 0.08 2.85 (1.29 – 6.30), 0.009 
Uninfected at 24 months 247 26 (11) 1.0 1.0 
Boys Age at VZV 
infection 
By 12 months   34 10 (29) 1.29 (0.59 – 2.82), 0.52 1.60 (0.70 – 3.67), 0.27 
12-24 months   64 12 (19) 0.71 (0.36 – 1.41), 0.33 0.79 (0.39 – 1.61), 0.52 
Uninfected at 24 months 299 73 (24) 1.0 1.0 
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Table 3. Number of positive reactions by allergen 507 
 Number of positive reactions >=3mm  
1 2 3 4 total 
Cat    1 (2%)   5 (5%)   5 (8%)   3 (12%)  
Dog   2 (4%)   0   2 (3%)   3 (13%)  
Grass mix 13 (23%)   6 (6%) 16 (25%)   6 (25%)  
Mite 1 (D. Pter) 27 (48%) 48 (46%) 20 (32%)   6 (25%)  
Mite 2 (D. Farin) 13 (23%) 45 (43%) 20 (32%)   6 (25%)  
 56 104 (52 children) 63 (21 children) 24 (6 children) 135 
 508 
